AstraZeneca’s (AZN) Overweight Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a research note published on Tuesday morning,Digital Look reports.

Several other brokerages also recently issued reports on AZN. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price target on shares of AstraZeneca in a report on Monday, November 10th. Shore Capital reaffirmed a “buy” rating and issued a £145 price objective on shares of AstraZeneca in a research report on Thursday, November 6th. Finally, Berenberg Bank boosted their target price on shares of AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of £138.

Read Our Latest Report on AstraZeneca

AstraZeneca Trading Down 0.1%

LON AZN traded down GBX 20.31 during mid-day trading on Tuesday, hitting £142.04. The company’s stock had a trading volume of 2,722,445 shares, compared to its average volume of 59,721,828. The stock’s fifty day simple moving average is £135.29 and its two-hundred day simple moving average is £121.88. AstraZeneca has a 52-week low of GBX 9,573.51 and a 52-week high of £143.12. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm has a market capitalization of £220.20 billion, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

Insider Activity at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. Insiders own 0.14% of the company’s stock.

Key AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: JPMorgan reaffirmed an “overweight” rating on AstraZeneca, which underpins analyst confidence in the stock’s outlook. Digital Look
• Positive Sentiment: AstraZeneca appointed Joris Silon as Head of Investor Relations — a hire that should improve investor communication and could reduce information friction for analysts and holders. AstraZeneca appoints Joris Silon as head of investor relations
• Positive Sentiment: Insider promotion: Rick Suarez was named head of the U.S. biopharmaceuticals unit, a continuity move that keeps experienced leadership in a key market. AstraZeneca names insider Rick Suarez head of US biopharmaceuticals unit
• Positive Sentiment: AstraZeneca entered a collaboration with BostonGene on AI-driven oncology work, bolstering its R&D pipeline potential in oncology and signaling continued investment in AI-enabled discovery. BostonGene teams up with AstraZeneca on AI-driven oncology
• Neutral Sentiment: London’s FTSE 100 hit a record high on healthcare gains — a favorable sector backdrop that may be supporting AZN but also encourages rotation across names. London’s FTSE 100 finishes at record high on healthcare gains
• Neutral Sentiment: Technical note: coverage flagged AZN has passed above its 200-day moving average — a bullish technical milestone that sometimes triggers short-term “sell the news” profit-taking and extra volatility. That dynamic likely contributed to today’s downward move. AstraZeneca (LON:AZN) Stock Passes Above 200 Day Moving Average – Time to Sell?

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Stories

• Five stocks we like better than AstraZeneca
• A month before the crash
• How a Family Trust May Be Able To Help Preserve Your Wealth
• Market Panic: Trump Just Dropped a Bomb on Your Stocks
• YDES Could Be 2026’s Biotech Breakthrough
• “Fed Proof” Your Bank Account with THESE 4 Simple Steps